ELMMB logo
Facebook logo Twitter logo
Menu

4.2.2 Antipsychotic depot injections

4.2.2 Antipsychotic depot injections


     4.2.2 Antipsychotic depot injections
          Can be used for maintenance when compliance is a problem. 
          AMBER          Flupentixol decanoate
                                 injection 20mg/ml, 1mL, 2mL 
                                concentrate injection 100mg/ml, 0.5mL, 1mL  
          AMBER          Fluphenazine decanoate
                                 injection 25mg/ml, 0.5ml amp, 
          AMBER          Haloperidol decanoate injection 100mg/mL
          AMBER          Pipotiazine palmitate injection 50mg/ml  
          AMBER          Zuclopenthixol decanoate injection 200mg/ml, 500mg/ml 
 
          Risperdal Consta®  
          Risperdal Consta® restricted use – request from doctor must be sent to chief pharmacist and medical director of Lancashire Care 
          Trust before authorised to prescribe
          RED                     Risperidone (Risperdal Consta®) injection 
                                      25mg, 37.5mg. 50mg
 
          Abilify Maintena®, Xeplion®
          Aripiprazole prolonged-release (PR) suspension for injection and Paliperidone palmitate (PR) suspension for injection are 
          recommended as treatment options in the maintenance treatment of schizophrenia in adult patients stabilised with oral
          aripiprazole where both of the following criteria are met;
 
          >     where treatment is in line with the recommendations within NICE CG178 for the use of depot or long-acting injectable
                 antipsychotic medication and
          >     where treatment is in line with the Lancashire Care Guidance for Prescribing Second Generation Long Acting 
                 Antipsychotic Injections  
 
          RED        Aripiprazole (Abilify Maintena®) prolonged release suspension for injection, 400mg powder and solvent
          RED        *Paliperidone (Xeplion®) prolonged release suspension for injection, 50mg, 75mg,100mg,150mg  
 
          Paliperidone palmitate prolonged release suspension for injection (six monthly)
          Paliperidone palmitate 6-monthly injection is recommended as a treatment option for the maintenance treatment of 
          schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable 
          products:
            >  where treatment is in line with the recommendations within NICE CG178 for the use of depot or long-acting injectable
                antipsychotic medications, and
            >  where treatment is in line with the Lancashire Care Guidance for Prescribing Second Generation Long Acting Antipsychotic
                injections
          RED Paliperidone palmitate prolonged release suspension for injection (six monthly) (Byannli)
 
 
*MHRA Drug Safety Alert - Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery 
 

Back to Main Chapter

  






All material in this section is aimed at health care professionals, but is information currently held in the public domain, members of the
public seeking advice on medicine-related matters are advised to speak with their GP, pharmacist, nurse or contact NHS111 Service 
    Email: info.elmmb@nhs.net
 
 Copyright© 2016 East Lancashire Medicines Management Board. 
 All rights reserved.  Disclaimer/Terms and conditions